Key Highlights
- USD 350 million is the private placement tied to the completed Velaris Therapeutics acquisition by Alaunos Therapeutics (NASDAQ:TCRT), per the 8-K dated October 13, 2026. The USD 2.62 quote is 82.5% above the USD 1.4357 placement price, own arithmetic on two published numbers.
- USD 150.0 million is the gross IPO raised by Iambic Therapeutics (NASDAQ:IAM), which priced 9,375,000 shares at USD 16.00 on October 14, 2026, per the prospectus. Published quotes of USD 20.65 to USD 21.39 sit 29.1% to 33.7% above the offer price, own arithmetic.
- 19.97% was the October 15, 2026 gain for Trinity Biotech (NASDAQ:TRIB), to USD 7.93, on 27,380 American depositary shares, USD 217,123 of turnover (own arithmetic). Published market value is USD 6.45 million, and the October 16 premarket quote fell 5.42% to USD 7.50.
- USD 0.0787 is the published quote for China SXT Pharmaceuticals (NASDAQ:SXTC), up 14.39% on 204.47 million shares. That is 94.8% below the USD 1.50 price of the USD 12 million registered direct offering announced on October 8, 2026, own arithmetic.
Alaunos Therapeutics (NASDAQ:TCRT)
Per the 8-K dated October 13, 2026, Alaunos completed its acquisition of Velaris Therapeutics through a two-step merger. Investors bought 687,789 common shares at USD 1.4357 and 243,063 Series C preferred shares at USD 1,435.70, which sums to USD 349.95 million (own arithmetic). Each preferred share converts into 1,000 common shares only after stockholder approval under Nasdaq rules; without approval, holders may demand cash settlement beginning six months after issuance. As-converted common shares total 358.59 million, against a published market capitalization of USD 7.67 million that appears to count only pre-deal stock. At USD 2.62 the as-converted count is worth USD 939.5 million, own arithmetic and not a quoted capitalization. The stock rose a reported 67.6% on October 13, then a further 20.13% on 13.91 million shares, USD 36.4 million of turnover (own arithmetic). A resale registration is due within 30 days of closing, a reverse split is on the proxy, and an October 5, 2026 filing disclosed a Nasdaq notice under Rule 5550(b)(1), which sets a USD 2.5 million equity minimum. Lead program VLR199 is guided to proof-of-concept data in 2028.
Iambic Therapeutics (NASDAQ:IAM)
Iambic priced at USD 16.00, the midpoint of a USD 15 to USD 17 range, and did not upsize the deal. J.P. Morgan, Jefferies, BofA Securities and Citigroup led the 9,375,000-share sale of Iambic Therapeutics (NASDAQ:IAM). An option on 1,406,250 more shares would raise the count of 47,400,796 post-offering shares by 3.0% (own arithmetic). Trading opened at USD 19.31, 20.7% above the offer, and reached USD 22.00. The published 13.11% gain to USD 21.39 implies a USD 18.91 reference price (own arithmetic) that does not tie to the offer, so the session is not confirmed. At USD 20.65, market value is USD 978.8 million (own arithmetic). Cash was USD 207.9 million at June 30, 2026, and net loss was USD 77.3 million in 2025 and USD 50.1 million in the first half of 2026. Adding gross proceeds gives USD 357.9 million, which covers 42.9 months at the first-half loss rate of USD 8.35 million a month (own arithmetic, net loss as proxy for cash burn). Lead program IAM1363, an oral HER2 inhibitor, is in a Phase 1/1b trial. Lock-up length is not disclosed.
Trinity Biotech (NASDAQ:TRIB)
No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026. Turnover of USD 217,123 on 27,380 American depositary shares, against an implied average volume of 18,253 (own arithmetic from rounded relative volume), shows that small orders moved the price of Trinity Biotech (NASDAQ:TRIB). Effective July 24, 2026 each ADS changed from 20 to 600 Class A ordinary shares, a 1-for-30 reverse ADS split that left 813,130 ADSs outstanding and aimed to restore the Nasdaq USD 1.00 minimum bid. The company announced compliance on August 14, 2026, with USD 7.0 million of added investment from Perceptive Advisors, and filed a registration statement for a securities offering on August 21. Offering terms are not disclosed in the filing reviewed, and any sale adds ADSs to a small base. Revenue fell 28.9% in 2025 to USD 43.79 million from USD 61.56 million (own arithmetic), with a net loss of USD 37.38 million. Cash and runway are not disclosed. A paid investor-awareness arrangement began in June 2026.
China SXT Pharmaceuticals (NASDAQ:SXTC)
The company release dated October 8, 2026 announced a sale of 8,000,000 Class A shares or pre-funded warrants at USD 1.50, for USD 12 million, with Univest Securities as placement agent. Investors also received 8,000,000 warrants at USD 2.75, exercisable for cash or on a zero-cash basis for up to 9 shares each, which allows up to 72 million shares (own arithmetic). A zero-cash exercise converts a warrant without paying the strike, so new supply can exceed the shares sold. Investors in China SXT Pharmaceuticals (NASDAQ:SXTC) hold a 30-day option on another USD 12 million, and no use of proceeds is stated. Consolidations of 1-for-150 on February 3, 2026 and, as reported, 1-for-80 on August 10 compound to 12,000-to-1 (own arithmetic), above the 250-to-1 threshold at which Nasdaq withholds a compliance period. Published EPS of negative 645.01 is a consolidation artefact, not independently confirmed. Published market capitalization of USD 0.70 to USD 0.82 million conflicts with USD 16.1 million of turnover (own arithmetic). No catalyst was identified for the 14.39% rise.
Where Things Stand
China SXT Pharmaceuticals (NASDAQ:SXTC) carries the most dilution risk on structure, while Alaunos ranks first on the raw ratio. Ranked by latest financing divided by published market capitalization (own arithmetic): Alaunos 45.6x, China SXT 14.6x to 17.1x, Trinity 1.1x, Iambic 0.15x. The Alaunos denominator excludes preferred stock, and the China SXT capitalization conflicts with its turnover. Trinity Biotech (NASDAQ:TRIB) rose without an identified catalyst. Iambic Therapeutics (NASDAQ:IAM) holds the strongest cash position. Next catalysts: the Alaunos proxy, the China SXT 30-day option, any Trinity prospectus supplement and Iambic analyst initiations.






Please wait processing your request...